

**28 November 2018**

**ASX Announcement**

**ADALTA (1AD) AGM RESULTS 2018**

**MELBOURNE Australia, 28 November, 2018:** The AdAlta Limited (1AD) 2018 Annual General Meeting (AGM) was held on 28<sup>th</sup> November at 3pm AEDT at Level 14, 330 Collins St. All resolutions were passed and in accordance with section 251AA of the Corporations Act 2001, a summary of voting is provided on page 2 of this announcement in relation to resolutions put to members at the meeting.

AdAlta Directors James Williams and Liddy McCall were re-elected and the remuneration report was approved.

The issue of 375,000 Options to CEO Sam Cobb was also approved. The purpose of this issue was to replace the options which were issued at the 2017 AGM, which related to the Company's previous lead program, AD-114 and made specific reference to that compound. During the 2018 financial year the Company moved from the first generation compound, AD-114 to a second generation compound, called AD-214, due to significant improvements made to the program and its additional attractiveness to patients and potential pharmaceutical partners. The issue of today's 375,000 Options were a direct replacement of the Options issued at the 2017 AGM and were issued on the same terms as previous options, with the vesting criteria updated to 'Release of Adalta compound for human trials.'

During the financial year AdAlta successfully completed a placement to institutional and sophisticated investors as well as a share purchase plan with existing shareholders, raising \$4.73 million for manufacturing and preclinical studies of the Company's lead candidate, AD-214. We are grateful of the support shown by both existing and new investors during that process.

AdAlta's Directors, John Chiplin and Robert, participated in this funding round and shareholders approved the participation of Directors and purchase of shares at today's meeting at the same price as institutional and existing shareholders.

The fund raising from July will be used to fund manufacturing and pre-clinical studies of AD-214, AdAlta's lead therapeutic program for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Funds will also be committed to internal research; pipeline development of new i-bodies and associated corporate costs. The Company will need to raise additional funding to take AD-214 through 4-week toxicology and Phase I studies and for the purpose of Listing Rule 7.1A and for all other purposes, approval was provided by Shareholders for the issue of equity securities totaling up to 10% of the issued capital of the Company.

# Disclosure of Proxy Votes

## AdAlta Limited

2018 Annual General Meeting

Wednesday, 28 November 2018



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1. Adoption of the Remuneration Report	P	19,554,543	17,869,670	155,154	120,000	1,529,719	20,194,446	155,154	2,083,479
2. Re-election of Director – James Williams	S	73,684,391	72,154,672	0	50,000	1,529,719	n/a	n/a	n/a
3. Re-election of Director – Liddy McCall	S	73,684,391	72,154,672	0	50,000	1,529,719	n/a	n/a	n/a
4. Issue of shares to John Chiplin	S	73,734,391	60,133,118	12,071,554	0	1,529,719	n/a	n/a	n/a
5. Issue of shares to Robert Peach	S	73,734,391	71,466,518	738,154	0	1,529,719	n/a	n/a	n/a
6. Approval of prior issue of securities under the Company's 15% placement capacity	S	70,290,058	68,673,245	87,094	50,000	1,529,719	n/a	n/a	n/a
7. Issuance of 375,000 Options to Samantha Cobb	S	19,554,543	17,390,670	634,154	120,000	1,529,719	n/a	n/a	n/a
8. Approval of 10% placement capacity (Special Resolution)	S	73,684,391	71,596,518	558,154	50,000	1,529,719	n/a	n/a	n/a

